Document


☐						Preliminary Proxy Statement
☐						Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐						Definitive Proxy Statement
☒						Definitive Additional Materials
☐						Soliciting Material Pursuant to § 240.14a-12

☒

No fee required.

☐

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1)

Title of each class of securities to which transaction applies:

(2)

Aggregate number of securities to which transaction applies:

(3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4)

Proposed maximum aggregate value of transaction:

(5)

Total fee paid:

☐

Fee paid previously with preliminary materials.

☐

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1)

Amount previously paid:

(2)

Form, Schedule or Registration Statement No.:

(3)

Filing party:

(4)

Date Filed:

On April 27, 2020, Codexis, Inc. (the “Company”) filed its Definitive Proxy Statement on Schedule 14A (the “Proxy Statement”) for the Company’s 2020 Annual Meeting of Stockholders with the Securities and Exchange Commission. The Proxy Statement was filed in connection with the Company’s 2020 Annual Meeting of Shareholders to be held on June 16, 2020 (the “Annual Meeting”). This proxy statement supplement to the Proxy Statement is being filed to provide additional information resulting from events that occurred subsequent to the distribution of the Proxy Statement for the Annual Meeting.

This proxy statement supplement supplements and amends the original definitive proxy statement of Codexis, Inc. (the “Company”), dated April 27, 2020 (the “Proxy Statement”) for the Company’s 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to provide additional information resulting from events that occurred subsequent to the distribution of the Proxy Statement for the Annual Meeting.

On May 26, 2020, Sierra Oncology, Inc. (“Sierra”), a publicly-traded drug development company, announced the appointment of Stephen Dilly, MBBS, Ph.D. as Sierra’s President, Chief Executive Officer and a member of Sierra’s board of directors, effective June 1, 2020. As disclosed in the Proxy Statement, Dr. Dilly has been nominated for election at the Annual Meeting to join the Company’s board of directors as a Class I director.

Other than the addition of the above to Dr. Dilly’s biographical information, no other changes have been made to the Proxy Statement and it continues to be in full force and effect as originally filed.


Filed by the Registrant ☒ Filed by a party other than the Registrant ☐